Skip to main content

Table 6 Mean changes in SF-12 physical and mental component summary scores by preswitch medication* among patients switched to lurasidone

From: Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia

 

Parameter

Quetiapine

Olanzapine

Risperidone

Aripiprazole

Ziprasidone

(n = 62)

(n = 24)

(n = 51)

(n = 44)

(n = 27)

Physical component summary

Baseline (SD)

45.8 (10.3)

50.1 (9.5)

48.1 (8.5)

46.9 (11.0)

48.6 (10.5)

LOCF (SD)

44.1 (9.6)

51.0 (8.8)

50.4 (8.8)

46.0 (10.1)

47.0 (9.9)

Mean change (SD)

-1.3 (9.0)

1.3 (6.0)

2.4 (9.1)

-2.1 (7.9)

-0.4 (6.8)

p-value

0.046

0.077

0.124

0.190

0.427

Mental component summary

Baseline (SD)

38.9 (10.9)

43.8 (12.8)

43.8 (10.9)

42.2 (9.8)

39.5 (10.0)

LOCF (SD)

44.2 (10.9)

44.3 (15.7)

46.2 (10.0)

45.1 (9.2)

44.9 (10.4)

Mean change (SD)

4.2 (11.3)

0.0 (15.0)

2.6 (10.8)

4.7 (10.4)

5.6 (10.2)

p-value

0.029

0.834

0.298

0.002

0.129

  1. *Patients eligible for evaluation in the analysis (N = 235) may have had non-missing values at baseline and ≥1 post-baseline value at study endpoint (LOCF) for any SF-12 items; n values may not sum to 235.